Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: A highly potent orally available CCR5 selective antagonist

Add time:07/13/2019    Source:sciencedirect.com

Based on the original spirodiketopiperazine design framework, further optimization of an orally available CCR5 antagonist was undertaken. Structural hybridization of the hydroxylated analog 4 derived from one of the oxidative metabolites and the new orally available non-hydroxylated benzoic acid analog 5 resulted in another potent orally available CCR5 antagonist 6a as a clinical candidate. Full details of a structure–activity relationship (SAR) study and ADME properties are presented.

We also recommend Trading Suppliers and Manufacturers of 2-(1-AMinoethyl)benzoic acid hydrochloride (cas 658683-12-6). Pls Click Website Link as below: cas 658683-12-6 suppliers

Prev:Structure–cytotoxicity relationship in a series of N-phosphorus substituted E,E-3,5-bis(3-pyridinylmethylene)- and E,E-3,5-bis(4-pyridinylmethylene)piperid-4-ones
Next:A simple synthesis of 4-(2-aminoethyl)-5-hydroxy-1H-pyrazoles)